Thus, resminostat-induced downregulation of zfp64 expression was found to take place also in the course of epi-virotherapeutic cotreatment (Res + MeV) of human hepatoma cells, indicating an unimpaired effect of resminostat in this specific epi-virotherapeutic context, a finding which is highly essential for the further clinical development of this combinatorial approach. This evidence concerns the gene ZFP64 and hepatocellular carcinoma.